Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

53.65USD
18 Jun 2018
Change (% chg)

$-1.15 (-2.10%)
Prev Close
$54.80
Open
$54.28
Day's High
$54.48
Day's Low
$53.52
Volume
2,541,518
Avg. Vol
2,161,013
52-wk High
$70.04
52-wk Low
$49.97

Select another date:

Mon, Jun 4 2018

The next battleground after SCOTUS' BMS ruling? Class actions, defense lawyers say

Product liability defense lawyers expect the U.S. Supreme Court to eventually look at making explicit that the restrictions it placed on where plaintiffs can bring injury claims in Bristol-Myers Squibb v. Superior Court of California also apply to class actions.

Mixed results for Bristol/Nektar combination in cancer trial

Chicago, June 3 Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

Supreme Court declines to hear Bristol-Myers whistleblower lawsuit

The U.S. Supreme Court on Tuesday said it would not take up a dismissed whistleblower lawsuit claiming Bristol-Myers Squibb Co and Otsuka Pharmaceutical engaged in a scheme to improperly promote the antipsychotic drug Abilify.

BRIEF-Omega Advisors Takes Share Stake In UnitedHealth, Bristol-Myers Squibb

* OMEGA ADVISORS DISSOLVES SHARE STAKE IN AMERICAN AIRLINES - SEC FILING

BRIEF-Bristol-Myers Squibb Elects Each Of Company's 12 Nominees To Serve As Directors

* BRISTOL-MYERS SQUIBB CO - SHAREHOLDERS ELECTED EACH OF COMPANY'S 12 NOMINEES TO SERVE AS DIRECTORS OF COMPANY UNTIL 2019 ANNUAL MEETING

BRIEF-EMA Validates Bristol-Myers' Type II Variation Application For Opdivo Plus Yervoy Combination For Treatment Of First-Line Metastatic Non-Small Cell Lung Cancer

* EUROPEAN MEDICINES AGENCY VALIDATES BRISTOL-MYERS SQUIBB'S TYPE II VARIATION APPLICATION FOR OPDIVO PLUS YERVOY COMBINATION FOR TREATMENT OF FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)

BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement

* BRISTOL-MYERS SQUIBB AND FLATIRON HEALTH EXPAND COLLABORATION WITH A THREE-YEAR AGREEMENT

BRIEF-Advantagene Announces Clinical Trial Collaboration

* ADVANTAGENE INC SAYS COMPANY ENTERED INTO A CLINICAL TRIAL COLLABORATION WITH BRISTOL-MYERS SQUIBB

Bristol-Myers raises 2018 forecast, some sales disappoint

NEW YORK Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

UPDATE 3-Bristol-Myers raises 2018 forecast, some sales disappoint

NEW YORK, April 26 Bristol-Myers Squibb Co on Thursday significantly raised its full-year earnings forecast even as first-quarter sales of some medicines fell short of expectations and sent shares of the U.S. drugmaker down almost 1 percent.

Select another date: